The role of flavin-containing monooxygenases in drug metabolism and development

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 4, 2003, Pages 486-493

  Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

ADME; Cytochrome P450; Drug design; Drug metabolism; Flavin containing monooxygenase; Lead optimization

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; BENZAMIDINE; DISULFIRAM; ITOPRIDE; MELAGATRAN; METHAMPHETAMINE; MOSAPRIDE CITRATE; NICOTINE; OLANZAPINE; PENTAMIDINE; QUERCETIN; SIBRAFIBAN; UNSPECIFIC MONOOXYGENASE;

DRUG DESIGN; DRUG METABOLISM; EVALUATION; HUMAN; NONHUMAN; OXYGENATION; QUANTITATIVE ANALYSIS; REDUCTION; REVIEW; XENOBIOTIC METABOLISM;

AMINES; ANIMALS; DRUG DESIGN; HUMANS; MONOAMINE OXIDASE; ORGAN SPECIFICITY; PHARMACEUTICAL PREPARATIONS; PRODRUGS;

EID: 0042029629     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Cashman JR: Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol (1995) 8(2):166-181. A comprehensive survey of animal and human FMOs.
2. Ziegler DM: Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol (1993) 33:179-199. A summary of the structure and function of FMO1 up to 1993.
3. Poulsen LL, Ziegler DM: The liver microsomal FAD-containing monooxygenases. Spectral characterization and kinetic studies. J Biol Chem (1979) 254(14):6449-6455.
4. Beaty NB, Ballou DP: The oxidative half-reaction of liver microsomal FAD-containing monooxygenase. J Biol Chem (1981) 256(9):4619-4625.
5. Guengerich FP: Cytochrome P450 enzymes. In: Comprehensive Toxicology. Sipes IG, McQueen CA, Gandolfi AJ (Eds), Elsevier Science, New York, NY, USA (1997):37-68. A good review of P450 enzymes.
6. Bruice TC, Noar JB, Ball SS, Venkataram UV: Monooxygen donation potential of 4a-hydroperoxyflavins as compared with those of percarboxylic acid and other hydroperoxides. Monooxygen donation to olefin, tertiary amine, alkyl sulfide, and iodide ion. J Am Chem Soc (1983) 105(8):2452-2463.
7. Lawton MP, Cashman JR, Cresteil T, Dolphin C, Elfarra A, Hines RN, Hodgson E, Kimura T, Ozols J, Phillips I, Philpot RM et al: A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys (1994) 308(1):254-257. A review of the nomenclature and genetic relatedness of the FMOs.
8. Whetstine JR, Yueh M-F, Hopp KA, McCarver DG, Williams DE, Park CS, Kang JH, Cha Y-N, Dolphin CT, Shephard EA, Phillips IR, Hines RN: Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: Detection of expressed protein In African Americans. Toxicol Appl Pharmacol (2000) 168(3):216-224.
9. Lomri N, Gu Q and Cashman JR: Molecular cloning of the flavin-containing monooxygenase (form II) cDNA from adult human liver. Proc Natl Acad Sci USA (1992) 89(5):1685-1689. The first report of the identification of human FMO3 cDNA.
10. Dolphin CT, Cullingford TE, Shephard EA, Smith RL, Phillips IR: Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FMO4. Eur J Biochem (1996) 235(3):683-689.
11. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, Cashman JR: Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: Comparative genetic and functional studies. Drug Metab Dispos (2003) 31(7):1-7. A report showing fast- and slow-metabolizer FMO3 phenotype.
12. Overby LH, Buckpit AR, Lawton MP, Atta-Assaafo-Adjei E, Schulze J, Philpot RM: Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: Evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog. Arch Biochem Biophys (1995) 317(1):275-284.
13. Cashman JR: Human flavin-containing monooxygenase: Substrate specificity and role in drug metabolism. Curr Drug Metab (2000) 1(2):181-191. A useful discussion of FMO substrate specificity.
14. Cashman JR, Xiong YN, Xu L, Janowsky A: N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): Role in bioactivation and detoxication. J Pharmacol Exp Ther (1999) 288(3):1251-1260.
15. Zhou S, Kestell P, Paxton JW: 6-Methylhydroxylation of the anticancer agent 5,6-dimethyl-xanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3. Eur J Drug Metab Pharmacokinet (2002) 27(3):179-183.
16. Fraaije MW, Kamerbeek NM, Van Derkel WJ, Janssen DB: Identification of a Baeyer-Villiger monooxygenase sequence motif. FEBS Lett (2002) 518(1-3):43-47.
17. Cashman JR: Monoamine oxidase and flavin-containing monooxygenase. In: Comprehensive Toxicology. Sipes IG, McQueen CA, Gandolfi AJ (Eds), Elsevier Science, New York, NY, USA (1997):69-96. A good review of FMO.
18. Kedderis GL, Rickert DE: Loss of rat liver microsomal cytochrome P450 during methimazole metabolism. Role of flavin-containing monooxygenase. Drug Metab Dispos (1985) 13(1):58-61.
19. Poulsen LL, Ziegler DM: Multisubstrate flavin-containing monooxygenases: Application of mechanism to specificity. Chem Biol Interact (1995) 96(1):57-73. A summary of FMO mechanism.
20. Ziegler DM: Flavin-containing monooxygenases: Enzymes adapted for multisubstrate specificity. Trends Pharmacol Sci (1990) 11(8):321-324.
21. Lin J, Cashman JR: Detoxication of tyramine by the flavin-containing monooxygenase: Stereoselective formation of the trans oxime. Chem Res Toxicol (1997) 10(8):842-852.
22. Lin J, Cashman JR: N-oxygenation of phenethylamine to the trans oxime by adult human liver flavin-containing monooxygenase and retroreduction of phenethylamine by human liver microsomes. J Pharmacol Exp Ther (1997) 282(3):1269-1279.
23. Cashman JR: Drug discovery and drug metabolism. Drug Disc Today (1996) 1(5):209-216.
24. DiMasi JA: Risks of new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther (2001) 69(5):297-307. A survey of success rates for NCEs.
25. Proudfoot JR: Drugs, lead, and drug-likeness: An analysis of some recently launched drugs. Bioorg Med Chem Lett (2002) 12(12):1647-1650. This interesting summary of drugs launched in 2000 shows that the leads were drug-like.
26. Clement B: Reduction of N-hydroxylated compounds: Amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev (2002) 34(3):565-579. A summary of the N-hydroxylated prodrug approach.
27. Clement B, Behrens D, Moller W, Cashman JR: Reduction of amphetamine hydroxylamine and other aliphatic hydroxylamines by benzamidoxime reductase and human liver microsomes. Chem Res Toxicol (2000) 13(10):1037-1045.
28. Clement B, Schultze-Mosgau MH, Richter PH, Besch A: Cytochrome P450 dependent N-hydroxylation of an aminoguanidine (amidinohydrazone) and microsomal retroreduction of the N-hydroxylated product. Xenobiotica (1994) 24(7):671-688.
29. Clement B, Demesmaeker M, Linne S: Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: Characterization of the two reactions and genotoxic potential of guanoxabenz. Chem Res Toxicol (1996) 9(4):682-688.
30. Van de Waterbeemd H, Smith DA, Beaumont K, Walker DK: Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem (2001) 44(9):1313-1333. A good perspective on absorption and pharmacokinetics.
31. Clement B: Oxidation and reduction of nitrogen via CYP450: Importance of the reduction of genotoxic N-hydroxylated functional groups. In: Drug Metabolism: Towards the Next Millennium. Gooderham NJ (Ed), IOS Press, Amsterdam, the Netherlands (1998):59-71.
32. Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, Hürzeler-Müller M, Knoop D, Levet-Trafit JB, Lipari MT, Modi NB et al: Orally active fibrinogen receptor antagosinsts. 2. Amidoximes as prodrugs of amidines. J Med Chem (1996) 39(16):3139-3147.
33. Gustaffsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K-J, Ungell A-L, Sörensen H et al: The direct thrombin inhibitor melagatran and Its oral prodrug H376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res (2001) 101(3):171-181.
34. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feidman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM et al: Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation (1998) 97(4):340-349.
35. Eriksson UG, Johannson L, Frison L, Bredberg U, Gustafsson D: Single and repeated oral dosing of H376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood (1999) 94(10 Suppl 1):Abs101.
36. Clement B, Jung F: N-hydroxylation and N-dealkylation by P450 2C3 of N-methylbenzamidine: N-oxygenation and N-oxidative dealkylation of one functional group. Xenobiotica (1995) 25(5):443-455.
37. Bernheim M: The hydroxylamine reductase of mitochondria. Arch Biochem Biophys (1969) 134(2):408-413.
38. 2 insensitive NADH-benzamidoxime reductase. J Biol Chem (1997) 272(31):19615-19620. A report characterizing the P450 that reduces hydroxylamines.
39. Patterson LH: Bioreductively activated anti-tumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev (2002) 34(3):581-592.
40. Cashman JR, Park SB, Yang ZC, Washington CB, Gomez DY, Giacomini KM, Brett CM: Chemical, enzymatic and human enantioselective S-oxygenation of cimetidine. Drug Metab Dispos (1993) 21(4):587-597. A detailed study of the in vitro and in vivo stereoselectivity of FMO.
41. Yeung CK, Lang DH, Thummel KE, Rettie AE: Immunoquantitation of FMO1 in human liver, kidney and intestine. Drug Metab Dispos (2000) 28(9):1107-1111.
42. Kim YM, Ziegler DM: Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Dispos (2000) 28(8):1003-1006.
43. Pike MG, Mays DC, Macomber DW, Lipsky JJ: Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin-monooxygenase in human renal microsomes. Drug Metab Dispos (2001) 29(2):127-131.
44. Decker MW, Brioni J, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJB, Giardina WJ, Wasicak J, Williams M, Arneric SP: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT418): A novel cholinergic ligand with cognition enhancing and anxiolytic activity. II. In vivo characterization. J Pharmacol Exp Ther (1994) 278(1):319-328.
45. Rodrigues AD, Kukulka MJ, Ferrero JL, Cashman JR: In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan Troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N′-oxidation. Drug Metab Dispos (1995) 23(10):1143-1152.
46. 3H) nicotine to liver and lung microsomal macromolecules. Drug Metab Dispos (1988) 16(3):397-402.
47. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P, Benowitz NL: Metabolism of nicotine by human liver microsomes: Stereoselective formation of trans-nicotine N-oxide. Chem Res Toxicol (1992) 5(5):639-646. The first report showing that CYP2A6 selectively oxidizes (S)-nicotine.
48. Iwanaga Y, Miyashita N, Morikawa K, Mizumoto A, Kondo Y, Itoh L: A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity: Comparison with demperidone and neostigmine. Gastroenterology (1990) 99(2):401-408.
49. Bedford TA, Rowbotharn DJ: Cisapride: Drug interactions of clinical significance. Drug Saf (1996) 15(3):167-175. A report outlining drug interactions with cisapride.
50. Mushiroda T, Douya R, Takahara E, Nagata O: The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: Comparison with cisapride and mosapride citrate. Drug Metab Dispos (2000) 28(10):1231-1237.
51. Cashman JR, Zhang J: Interindividual differences of human flavin-containing monooxygenase 3: Genetic polymorphisms and functional variation. Drug Metab Dispos (2002) 30(10):1043-1052. A summary of the genetic polymorphisms of FMO3.
52. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NO: The pharmacology of olanzapine and other new antipsychotic agents. Expert Opin Investig Drugs (1993) 2:281-293.
53. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA: Identification of the human cytochromes P-450 responsible for the in vivo formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther (1996) 276(2):658-666.